Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Q3 2025 Earnings Presentation
16 slides from Vivoryon Therapeutics's earnings presentation, Dec 4, 2025
Slide 1: Q3 Financial Results and Business Update
Q3 Financial Results and Business Update Webcast and Conference Call December 4, 2025 Vivoryon Therapeutics N.V.
Slide 2: Important notice and disclaimer
Important notice and disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Agenda
Agenda Recent Key Achievements Q&A Julia Neugebauer, PhD Chief Operating Officer Frank Weber, MD Chief Executive Officer Advancing Strategic Priorities Julia Neugebauer, PhD Chief Operating Officer Frank Weber, MD Chief Executive Officer Michael Schaeffer, PhD Chief Business Officer Financial Result
Slide 4: Recent Key Achievements
Recent Key Achievements Julia Neugebauer, PhD COO
Slide 5: Continuing to build robust body of evidence for varoglutamstat in kidney disease and beyond
Continuing to build robust body of evidence for varoglutamstat in kidney disease and beyond ◆ Compelling kidney function & biomarker data presented for varoglutamstat at ASN 2025, Lead the world’s premier nephrology meeting Program ◆ New Ph 2 analysis of pooled data in patients with impaired kidney
Slide 6: Advancing Strategic Priorities
Advancing Strategic Priorities Frank Weber, MD CEO
Slide 7: Varoglutamstat: Potential to become a convenient new oral therapy for kidney disease
Varoglutamstat: Potential to become a convenient new oral therapy to transform the treatment of kidney disease Current landscape Medical Need Opportunity ◆ Treatments for CKD/DKD ◆ Novel, convenient ◆ Varoglutamstat is a novel, have advanced with therapies are needed first-in-class oral compound rec
Slide 8: New analysis showed consistent treatment effect in patients with impaired kidney function
New analysis from Phase 2 program showed consistent and pronounced treatment effect in patients with impaired kidney function (low baseline eGFR) Effect size fully maintained in patients with impaired kidney function (baseline eGFR lower 33%), consistent with results for all participants in the tota
Slide 9: Varoglutamstat improved eGFR in patients with lower baseline eGFR and diabetes
Varoglutamstat showed consistent and strong improvement of eGFR in patients with lower baseline eGFR values and diabetes Participants with diabetes & reduced kidney function (baseline eGFR levels in lower percentiles within the diabetes subgroup*; Treatment effect (annualized rate of change in eGFR
Slide 10: Development opportunities for QPCT/L inhibitors across immune-mediated diseases
Development opportunities for QPCT/L inhibitors range across many immune-mediated diseases characterized by inflammation and fibrosis Broad potential for QPCT/L inhibitors: Multiple avenues to value generation Leveraging proprietary QPCT/L platform and core expertise to generate additional developme
Slide 11: Financial Results
Financial Results Marcus Irsfeld CFO
Slide 12: Key financial figures
Key financial figures In €k Nine months ended Nine months ended Sep 30, 2025 Sep 30, 2024 Revenue 0 0 Research & Development expenses (3,667) (12,582) General & Administrative expenses (4,005) (4,897) Net loss for the period (7,622) (17,143) In €k Sep 30, 2025 Dec 31, 2024 Cash & cash equivalents 2,
Slide 13: Summary
Summary
Slide 14: Vivoryon's approach and expertise positions company for future growth
Vivoryon’s approach and expertise positions company for future growth and supports development of innovative oral therapies for kidney disease and beyond High medical need in kidney Varoglutamstat poised to address Broad potential for QPCT/L disease unmet needs inhibitors ◆ No approved therapies ava
Slide 15: Q&A
Q&A
Slide 16: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany [email protected] +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Q3 2025 Earnings Presentation on 6ix